Syndax Pharmaceuticals (SNDX) Moved, What Is Behind The Fresh Attention?
Syndax Pharmaceuticals (SNDX) has moved into focus after terminating a long running license arrangement that affected China rights for Entinostat, just as it reported second quarter 2026 results with higher revenue and a narrower net loss.
See our latest analysis for Syndax Pharmaceuticals.
The recent move by Syndax Pharmaceuticals to end the China Entinostat license arrangement arrives after a weak 30 day share price return of 15.65% and a year to date share price return of 6.85%. However, the 1 year total shareholder return of 26.05% and 5 year total shareholder return of 25.97% still point to a stock where longer term holders have seen more support than short term traders.
If this kind of news driven volatility has your attention, it can be helpful to compare Syndax with other cancer and immunology focused biotech stocks using our screener of 44 healthcare AI stocks
Syndax Pharmaceuticals now has stronger recent revenue figures on the table along with a reset China position. Does that combination justify buying at today’s price, or does it make more sense to wait for a cleaner entry point as the story unfolds?
Most Popular Narrative: 50% Undervalued
The most followed narrative currently anchors Syndax Pharmaceuticals at a fair value of $39.50 compared with the recent close of $19.84, which creates a wide valuation gap that hinges on aggressive long term growth expectations and future profitability.
Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for innovative, targeted therapies, supporting sustained multi-year earnings momentum.
Want to see what kind of revenue curve and margin lift that narrative is baking in for Syndax Pharmaceuticals. The assumptions go far beyond simple top line growth and require a step change in profitability and valuation multiples that many investors might not expect at first glance.
Result: Fair Value of $39.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Syndax Pharmaceuticals still faces key risks, including setbacks for Revuforj or Niktimvo and slower than expected label expansions that could undermine the positive earnings outlook.
Find out about the key risks to this Syndax Pharmaceuticals narrative.
Next Steps
With sentiment clearly split on Syndax Pharmaceuticals, this is a good moment to act promptly, review the underlying data, and shape your own view using the 2 key rewards.
Looking for more investment ideas beyond Syndax Pharmaceuticals?
If Syndax Pharmaceuticals has you thinking more broadly about your portfolio, now is the time to scan for other opportunities before the next wave of ideas passes by.
- Spot early stage potential by reviewing 18 elite penny stocks with strong financials that combine smaller market caps with stronger financial footing than many investors might expect.
- Zero in on value by using the 50 high quality undervalued stocks to find stocks where current prices sit below fundamentals based on cash flows and balance sheet strength.
- Strengthen portfolio resilience by checking the solid balance sheet and fundamentals stocks screener (50 results) and filter for companies that pair manageable debt with healthier financial foundations.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com